The Alzheimer’s economy: is the new $56,000-a-year drug worth it?
阿爾茨海默氏症經濟：每年56,000美元的新藥值得嗎？

US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
百健公司的治療方法在美國獲批，給患者帶來了希望。但一些專家擔心期望值被抬得太高了。